Da Volterra Receives first Authorizations from Regulatory Authorities in EU Countries to Initiate Phase 3 Clinical Trial Evaluating Microbiome Protector DAV132
Da Volterra, a clinical-stage biopharmaceutical company developing innovative products to prevent the life-threatening effects antibiotics have on the gut microbiome of cancer patients, announced today that it received approval to start enrolling patients in a […]
